Кудайбергенова А. Г.¹, Горбань Н. А.²

¹ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Петрова» Минздрава России; Россия, 197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68;

²ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской Федерации; Россия, 121359 Москва, ул. Маршала Тимошенко, 15

1. Sun T., Zhang H., Gao W., Yang Q. The appropriate number of preoperative core needle biopsy specimens for analysis in breast cancer. Medicine (Baltimore) 2021;100(14):e25400. DOI: 10.1097/ MD.0000000000025400

2. WHO Classification of Tumours Editorial Board. Breast tumours. 5th edn, vol. 2. Lyon: International Agency for Research on Cancer, 2019.

3. Ellis I.O., Elston C.W. Histologic grade. In: Breast Pathology. Philadelphia: Elsevier, 2006. Pp. 225–233.

4. Горбань Н.А., Кудайбергенова А.Г., Филатова А.В., Гаврилов А.М. Протоковая карцинома in situ молочной железы. Аспекты морфологической диагностики. Онкопатология 2020;3(1–2):33–41. Gorban N.A., Kudaybergenova A.G., Filatova A.V., Gavrilov A.M. Ductal carcinoma in situ of the breast. Aspects of morphological diagnostics. Onkopatologiya = Oncopathology 2020;3(1–2):33–41. (In Russ.)

5. Royal College of Pathologists. Pathology Reporting of Breast Disease in Surgical Excision Specimens Incorporating the Dataset for Histological Reporting of Breast Cancer. Available at: https:// www.rcpath.org/profession/publications/cancer-datasets.html.

6. Gradishar W.J., Anderson B.O., Abraham J. et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18(4):452–78. DOI: 10.6004/ jnccn.2020.0016

7. Allison K.H., Hammond E.H., Dowsett M. et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med 2020;144(5):545–63. DOI: 10.5858/ arpa.2019-0904-SA

8. Wolff A.C., Hammond M.E.H., Allison K.H. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 2018;36(20):2105–22. DOI: 10.1200/JCO.2018.77.8738

9. Venetis K., Crimini E., Sajjadi E. et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci 2022;15(9):834651. DOI: 10.3389/fmolb.2022.834651

10. Nielsen T.O., Leung S.C.Y., Rimm D.L. et al. Assessment of Ki-67 in breast cancer: updated recommendations from the International Ki-67 in Breast Cancer Working Group. J Natl Cancer Inst 2021;113(7):808–19. DOI: 10.1093/jnci/djaa201

11. Семиглазов В.Ф., Апанасевич В.И., Бесова Н.С. и др. «Золотой стандарт» диагностики и лечения рака молочной железы 2021. М.: ООО «Издательский дом «АБВ-пресс», 2020. 173 c. Доступно по: https://specialist.nnood.ru/wp-content/uploads/ sites/3/2021/01/KR_ROOM_2021_Zolotoy_standart_NEW.pdf. Semiglazov V.F., Apanasevich V.I., Besova N.S. et al. The gold standard of breast cancer diagnosis and treatment 2021. Moscow: Publishing house “ABV-press”, 2020. 173 p. Available at: https://specialist.nnood.ru/wp-content/uploads/ sites/3/2021/01/KR_ROOM_2021_Zolotoy_standart_NEW.pdf. (In Russ.)